<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Srivastava S</submitter><funding>NIAID NIH HHS</funding><pagination>1951-9</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3209814</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>204(12)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>It is believed that nonadherence is the proximate cause of multidrug-resistant tuberculosis (MDR-tuberculosis) emergence. The level of nonadherence associated with emergence of MDR-tuberculosis is unknown. Performance of a randomized controlled trial in which some patients are randomized to nonadherence would be unethical; therefore, other study designs should be utilized.&lt;h4>Methods&lt;/h4>We performed hollow fiber studies for both bactericidal and sterilizing effect, with inoculum spiked with 0.5% rifampin- and isoniazid-resistant isogenic strains in some experiments. Standard therapy was administered daily for 28-56 days, with extents of nonadherence varying between 0% and 100%. Sizes of drug-resistant populations were compared using analysis of variance. We also explore</pubmed_abstract><journal>The Journal of infectious diseases</journal><pubmed_title>Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.</pubmed_title><pmcid>PMC3209814</pmcid><funding_grant_id>R01AI079497</funding_grant_id><funding_grant_id>R01 AI079497</funding_grant_id><pubmed_authors>Srivastava S</pubmed_authors><pubmed_authors>Meek C</pubmed_authors><pubmed_authors>Leff R</pubmed_authors><pubmed_authors>Pasipanodya JG</pubmed_authors><pubmed_authors>Gumbo T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.</name><description>&lt;h4>Background&lt;/h4>It is believed that nonadherence is the proximate cause of multidrug-resistant tuberculosis (MDR-tuberculosis) emergence. The level of nonadherence associated with emergence of MDR-tuberculosis is unknown. Performance of a randomized controlled trial in which some patients are randomized to nonadherence would be unethical; therefore, other study designs should be utilized.&lt;h4>Methods&lt;/h4>We performed hollow fiber studies for both bactericidal and sterilizing effect, with inoculum spiked with 0.5% rifampin- and isoniazid-resistant isogenic strains in some experiments. Standard therapy was administered daily for 28-56 days, with extents of nonadherence varying between 0% and 100%. Sizes of drug-resistant populations were compared using analysis of variance. We also explore</description><dates><release>2011-01-01T00:00:00Z</release><publication>2011 Dec</publication><modification>2025-04-04T22:24:06.807Z</modification><creation>2019-03-27T00:45:46Z</creation></dates><accession>S-EPMC3209814</accession><cross_references><pubmed>22021624</pubmed><doi>10.1093/infdis/jir658</doi></cross_references></HashMap>